380 related articles for article (PubMed ID: 31628668)
1. Dose-Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs.
Mori D; Kimoto E; Rago B; Kondo Y; King-Ahmad A; Ramanathan R; Wood LS; Johnson JG; Le VH; Vourvahis M; David Rodrigues A; Muto C; Furihata K; Sugiyama Y; Kusuhara H
Clin Pharmacol Ther; 2020 Apr; 107(4):1004-1013. PubMed ID: 31628668
[TBL] [Abstract][Full Text] [Related]
2. Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.
Takehara I; Yoshikado T; Ishigame K; Mori D; Furihata KI; Watanabe N; Ando O; Maeda K; Sugiyama Y; Kusuhara H
Pharm Res; 2018 May; 35(7):138. PubMed ID: 29748935
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I.
Barnett S; Ogungbenro K; Ménochet K; Shen H; Humphreys WG; Galetin A
J Pharmacol Exp Ther; 2019 Jan; 368(1):125-135. PubMed ID: 30314992
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
5. Quantitative prediction of OATP1B-mediated drug-drug interactions using endogenous biomarker coproporphyrin I.
Takubo H; Bessho K; Watari R; Shigemi R
Xenobiotica; 2022 Apr; 52(4):397-404. PubMed ID: 35638858
[TBL] [Abstract][Full Text] [Related]
6. Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation.
Barnett S; Ogungbenro K; Ménochet K; Shen H; Lai Y; Humphreys WG; Galetin A
Clin Pharmacol Ther; 2018 Sep; 104(3):564-574. PubMed ID: 29243231
[TBL] [Abstract][Full Text] [Related]
7. Biomarker-Informed Model-Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug-Drug Interactions.
Kimoto E; Costales C; West MA; Bi YA; Vourvahis M; David Rodrigues A; Varma MVS
Clin Pharmacol Ther; 2022 Feb; 111(2):404-415. PubMed ID: 34605015
[TBL] [Abstract][Full Text] [Related]
8. In Vitro-In Vivo Extrapolation of OATP1B-Mediated Drug-Drug Interactions in Cynomolgus Monkey.
Ufuk A; Kosa RE; Gao H; Bi YA; Modi S; Gates D; Rodrigues AD; Tremaine LM; Varma MVS; Houston JB; Galetin A
J Pharmacol Exp Ther; 2018 Jun; 365(3):688-699. PubMed ID: 29643253
[TBL] [Abstract][Full Text] [Related]
9. Alteration in the Plasma Concentrations of Endogenous Organic Anion-Transporting Polypeptide 1B Biomarkers in Patients with Non-Small Cell Lung Cancer Treated with Paclitaxel.
Mori D; Ishida H; Mizuno T; Kusumoto S; Kondo Y; Izumi S; Nakata G; Nozaki Y; Maeda K; Sasaki Y; Fujita KI; Kusuhara H
Drug Metab Dispos; 2020 May; 48(5):387-394. PubMed ID: 32114508
[TBL] [Abstract][Full Text] [Related]
10. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
[TBL] [Abstract][Full Text] [Related]
11. Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.
Mori D; Kashihara Y; Yoshikado T; Kimura M; Hirota T; Matsuki S; Maeda K; Irie S; Ieiri I; Sugiyama Y; Kusuhara H
Drug Metab Pharmacokinet; 2019 Feb; 34(1):78-86. PubMed ID: 30528195
[TBL] [Abstract][Full Text] [Related]
12. Coproporphyrin I as an Endogenous Biomarker to Detect Reduced OATP1B Activity and Shift in Elimination Route in Chronic Kidney Disease.
Takita H; Scotcher D; Chu X; Yee KL; Ogungbenro K; Galetin A
Clin Pharmacol Ther; 2022 Sep; 112(3):615-626. PubMed ID: 35652251
[TBL] [Abstract][Full Text] [Related]
13. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
[TBL] [Abstract][Full Text] [Related]
14. A Microdose Cocktail to Evaluate Drug Interactions in Patients with Renal Impairment.
Tatosian DA; Yee KL; Zhang Z; Mostoller K; Paul E; Sutradhar S; Larson P; Chhibber A; Wen J; Wang YJ; Lassman M; Latham AH; Pang J; Crumley T; Gillespie A; Marricco NC; Marenco T; Murphy M; Lasseter KC; Marbury TC; Tweedie D; Chu X; Evers R; Stoch SA
Clin Pharmacol Ther; 2021 Feb; 109(2):403-415. PubMed ID: 32705692
[TBL] [Abstract][Full Text] [Related]
15. Absence of OATP1B (Organic Anion-Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression.
Zhang Y; Chen C; Chen SJ; Chen XQ; Shuster DJ; Puszczalo PD; Fancher RM; Yang Z; Sinz M; Shen H
J Pharmacol Exp Ther; 2020 Oct; 375(1):139-151. PubMed ID: 32719071
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
[TBL] [Abstract][Full Text] [Related]
17. Utilization of OATP1B Biomarker Coproporphyrin-I to Guide Drug-Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry.
Kikuchi R; Chothe PP; Chu X; Huth F; Ishida K; Ishiguro N; Jiang R; Shen H; Stahl SH; Varma MVS; Willemin ME; Morse BL
Clin Pharmacol Ther; 2023 Dec; 114(6):1170-1183. PubMed ID: 37750401
[TBL] [Abstract][Full Text] [Related]
18. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
[TBL] [Abstract][Full Text] [Related]
19. Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition.
Shen H; Christopher L; Lai Y; Gong J; Kandoussi H; Garonzik S; Perera V; Garimella T; Humphreys WG
Drug Metab Dispos; 2018 Aug; 46(8):1075-1082. PubMed ID: 29777022
[TBL] [Abstract][Full Text] [Related]
20. Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion.
Takehara I; Watanabe N; Mori D; Ando O; Kusuhara H
J Pharm Sci; 2019 Aug; 108(8):2756-2764. PubMed ID: 30905707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
